| Primary | Mean Plasma Glucose (MPG) Throughout Hospital Study Period | Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10. | All randomized participants who had at least one post-baseline glucose measurement. | Posted | | Mean | Standard Deviation | milligrams per deciliter (mg/dL) | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000167.6± 48.5
- OG001128.4± 22.4
|
|
| |
| Primary | Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period | Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm. | All randomized participants who had at least one post-baseline glucose measurement. | Posted | | Number | | percentage of capillary PG measurements | | Throughout hospital study period (1 to 10 days post-randomization) | capillary plasma glucose measurements | Participants | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Mean Plasma Glucose (MPG) by Hospital Day | The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7. | All randomized participants who had at least one post-baseline glucose measurement and a plasma glucose measurement at specified timepoint. | Posted | | Mean | Standard Deviation | mg/dL | | Day 1 up to day 7 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Mean Fasting Plasma Glucose (FPG) by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Mean FPG Throughout Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout the hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout the hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout the hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Capillary PG Measurements >240 mg/dL by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Total Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout the hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | TDD of Insulin (Units/kg) Throughout the Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout the hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | TDD of Insulin (Units) by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | TDD of Insulin (Units/kg) by Hospital Day | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Length of Hospital Stay Post-randomization Throughout the Hospital Study Period | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout the hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period | Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. | All randomized participants who had at least one post-baseline glucose measurement. | Posted | | Number | | hypoglycemic episodes | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
|
| Secondary | Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period | Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day | Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day | Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Day 1 up to day 10 of hospital study period | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period | Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module. | All randomized participants | Posted | | Number | | participants | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants Requiring Intensive Care Unit Transfer | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period | Deterioration of renal function was defined by an increase in serum creatinine by >0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Percentage of Participants With Documented Nosocomial Infections | Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |
| Secondary | Number of Participants With Major Adverse Cardiovascular Events (MACE) | MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed. | Due to low enrollment, zero participants were analyzed. | Posted | | | | | | Throughout hospital study period (1 to 10 days post-randomization) | | | | ID | Title | Description |
|---|
| OG000 | Sliding Scale Regular Insulin | Human regular insulin: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization). | | OG001 | Basal-bolus Therapy | Insulin lispro: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). Insulin glargine: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization). |
| |